# A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Source: https://onco.cc/trials/nct02711553/  
OnCo record `nct02711553` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ramucirumab, Cisplatin, Gemcitabine in metastatic cancer, run by Eli Lilly and Company, active and no longer recruiting.

## Summary

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer is a phase 2 interventional study registered as NCT02711553 by Eli Lilly and Company, with 309 participants enrolled, started 2016-05-19 and due to reach its primary completion in 2018-02-16. Interventions recorded: Ramucirumab, Merestinib, Cisplatin, Gemcitabine, Placebo Oral. Conditions listed: Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer. Results were posted on ClinicalTrials.gov in 2021; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: ctgov-ingest
- Registry id: NCT02711553
- Phase: 2
- Setting: Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
- Sponsor: Eli Lilly and Company
- Enrolled: 309
- Outcomes: Progression Free Survival (PFS): 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine 6.47 months vs 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine 6.97 months vs Pooled Placebo 6.64 months; Overall Survival (OS): 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine 10.45 months vs 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine 14.03 months vs Pooled Placebo 13.04 months; Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR): 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine 31.1% vs 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine 19.6% vs Pooled Placebo 32.7%

## Sources

- ClinicalTrials.gov NCT02711553: https://clinicaltrials.gov/study/NCT02711553

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Merestinib](https://onco.cc/drugs/merestinib/), [Ramucirumab](https://onco.cc/drugs/ramucirumab/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct02711553.json